CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, today announced that it was added to the Russell 3000®, Russell 2000®, and Russell Global Indexes when the Russell Investment Group reconstituted its family of U.S. indexes after the stock market close on June 27, 2014.
Help employers find you! Check out all the jobs and post your resume.
